Dual-energy X-ray absorptiometry (DXA) is the reference method for the measurement of bone mineral mass at different skeletal sites. It has been widely used in recent years to assess the effects of growth hormone (GH) treatment on bone metabolism. In normal individuals, bone mineral content (BMC) and density (BMD), as assessed using DXA, correlate with body size. Therefore, using DXA in patients with congenital GH deficiency (GHD), who have a smaller body frame, would be expected to result in lower bone mass. Thus, comparisons with reference data derived from populations of normal body size are invalid. The evaluation of the effects of GH administration should take into account the possible effects of GH on bone size, not only in children, but also in adults. The enlargement of bone, due to stimulation of the periosteal apposition, may partially mask an increase in BMC, resulting in little or no change in BMD. The ability of GH to affect bone area therefore requires analysis of the possible changes in bone area and BMC, as well as BMD. This issue has been poorly handled in the studies published to date. Lastly, the acceleration of bone turnover induced by GH leads to an increase in bone remodelling space, which in turn is associated with a reduction in BMC and BMD, independent of the net balance between breakdown and formation in each metabolic unit. This bone loss is completely reversible when the remodelling space returns to previous levels. This phenomenon must be taken into account when analysing the effects of GH treatment on bone mass, because a net gain in bone mass may be found in long-term GH treatment or after GH discontinuation, even if bone loss was evident during the first 6 months of treatment. In conclusion, the interpretation of bone density data in patients with GHD, and after GH administration, should take into account some of the methodological aspects of bone densitometry, as well as the specific actions of GH on bone metabolism and body composition.

Keywords:
Growth hormone, Bone densitometry, Bone mineral density, Dual-energy X-ray absorptiometry
1.
Cameron J, Sorenson J: Measurement of bone mineral in vivo: An improved method. Science 1963;12:230–232.
2.
Reed GW: The assessment of bone mineralization from the relative transmissions of 241Am and 137Cs radiations. Phys Med Biol 1966;11:174.
3.
Mazess RB, Ort M, Judy P, Mather W: Absorptiometric bone mineral determination using 153Gd; in Cameron JR (ed): Proceedings of Bone Measurement Conference (Conf. 700515). Washington, DC, US Atomic Energy Commission, 1970, pp 308–312.
4.
Wahner HW, Fogelman I: The evaluation of osteoporosis: Dual-energy X-ray absorptiometry in clinical practice. London, Martin Dunitz, 1994.
5.
Trevisan C, Ortolani S, Bianchi ML, Caraceni MP, Ulivieri FM, Gandolini G, Polli EE: Age, time since menopause, and body parameters as determinants of female spinal bone mass: A mathematical model. Calcif Tissue Int 1991;49:1–5.
6.
Sartorio A, Ortolani S, Conti A, Cherubini R, Galbiati E, Faglia G: Effects of recombinant growth hormone treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency. J Endocrinol Invest 1996;19:524–529.
7.
Tothill P, Pye DW: Errors due to non-uniform distribution of fat in dual X-ray absorptiometry of the lumbar spine. Br J Radiol 1992;65:807–813.
8.
Johansson AG, Engstrom BE, Ljunghall S, Karlsson FA, Burman P: Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999;84:2002–2007.
9.
Russell-Aulet M, Shapiro B, Jaffe CA, Gross MD, Barkan AL: Peak bone mass in young healthy men is correlated with the magnitude of endogenous growth hormone secretion. J Clin Endocrinol Metab 1998;83:3463–3468.
10.
Bravenboer N, Holzmann P, de Boer H, Roos JC, van der Veen EA, Lips P: The effect of growth hormone on histomorphometric indices of bone structure and bone turnover in GH-deficient men. J Clin Endocrinol Metab 1997;82:1818–1822.
11.
Longobardi S, Di Rella F, Pivonello R, Di Somma C, Klain M, Maurelli L, Scarpa R, Colao A, Merola B, Lombardi G: Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adult onset GH deficient patients. J Endocrinol Invest 1999;22:333–339.
12.
Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J: Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 1998;48:561–568.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.